JAMA Study Highlights Increased Gastrointestinal Risks of Popular GLP-1 Agonists

A study published in JAMA showed that glucagon-like peptide 1 (GLP-1) agonists medications used for weight loss — Ozempic and Wegovy (both semaglutide) and Mounjaro (liraglutide) — come with increased risks of gastrointestinal adverse events such as pancreatitis, bowel obstruction, and gastroparesis, the slowing or stopping of the movement of food from the stomach to the small intestine.
Source: Drug Industry Daily